Company / Operating Cash Flow per Share
Xenon Pharmaceuticals Inc. Operating Cash Flow per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
-$3.52
FY2025
5-year range
-$3.52 / -$1.59
FY2021-FY2025
Trend
-51.2%
vs FY2024
Sector context
#178 of 212
Health Care
What the data says
Xenon Pharmaceuticals Inc.'s operating cash flow per share of $-3.52 is lower than 84% of companies in the Health Care sector (FY2025). Operating Cash Flow per Share has declined for 6 consecutive years, from $-0.18 in FY2019 to $-3.52 in FY2025.
Based on SEC 10-K filings.
-3.52 in FY2025.
Declined from $-2.26 to $-3.52 over the past 2 years.
Health Care sector context is included.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 16% in Health CareTop 84% of 212This company -$3.52 Sector average -$14.72
▼
+76.1% above sector average
Key checks
Key Insights
- Xenon Pharmaceuticals Inc.'s operating cash flow per share has declined for 6 consecutive years.
- In FY2025, operating cash flow per share decreased 51.2% year-over-year.
- Ranks #178 out of 212 companies in the Health Care sector.
- Peak operating cash flow per share was recorded in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 3.51 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$3.52 | -51.2% |
| FY2024 | -$2.33 | -3.1% |
| FY2023 | -$2.26 | -35.4% |
| FY2022 | -$1.67 | -4.7% |
| FY2021 | -$1.59 | -14.3% |
| FY2020 | -$1.39 | -666.6% |
| FY2019 | -$0.18 | +90.6% |
| FY2018 | -$1.93 | -91.1% |
| FY2017 | -$1.01 | +25.8% |
| FY2016 | -$1.36 | -6.6% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026